JNJ - Johnson & Johnson
| Previous close | 144.56 |
| Open | 144.32 |
| Bid | 143.55 x 1000 |
| Ask | 143.56 x 800 |
| Day's range | 143.02 - 144.58 |
| 52-week range | 109.16 - 157.00 |
| Volume | 3,383,809 |
| Avg. volume | 11,875,277 |
| Market cap | 378.869B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 22.43 |
| EPS (TTM) | 6.41 |
| Earnings date | 16 Jul 2020 |
| Forward dividend & yield | 4.04 (2.80%) |
| Ex-dividend date | 22 May 2020 |
| 1y target est | 164.17 |
- Motley Fool
5 Dividend Kings to Buy and Hold Forever
The "forever" part means investors have to think about the longevity of payout growth as well as reliable payments.
- Yahoo Finance
Novavax expects COVID-19 vaccine trial results in July
Biotech firm Novavax has entered its coronavirus vaccine in a Phase 1 clinical trial in Australia — the first in the Southern Hemisphere.
- Zacks
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
The Zacks Analyst Blog Highlights: Bristol-Myers, Roche, AstraZeneca, Merck and Johnson & Johnson
- Motley Fool
3 Dividend Stocks Ideal for Retirees
Dividend stocks are a great option for a retirement account since you're earning income simply for holding shares. The coronavirus pandemic caused many companies to cut or cancel dividends. While other businesses saw substantial revenue declines from the current economic slowdown, there were at least three that delivered revenue and dividend increases in these tough economic times.
- Bloomberg
The More Covid-19 Vaccines, the Merrier
(Bloomberg Opinion) -- The way the Covid-19 crisis ends is with vaccines — not a vaccine. More than one horse can win this race. Some of us might end up getting a shot of a more traditional vaccine, which uses parts of an inactivated virus to stimulate immunity. Others might get vaccines based on emerging technologies that use synthetic versions of the virus’s genetic code.One such novel candidate, based on RNA and made by Moderna, showed promising results in early human trials, though critics warned the evidence is preliminary. Meanwhile, a different prototype based on DNA made headlines for an experiment that showed it worked in monkeys.In the end, some vaccines might be extremely effective but harder to scale; others the opposite. Even a less-effective vaccine might work well enough to provide herd immunity in a wider population. Other vaccines might be more appropriate for health care workers, who have to risk exposure on the job, and need protection as soon as possible.Scientists have created more than 70 vaccine candidates so far. “If we end up with two, three, or four vaccines, that’s good, since we have seven billion people,” says Harvard vaccine researcher Dan Barouch, who led the development of one of the vaccines featured in recent news. His group began working on a vaccine in January, after the virus started spreading in China. There are good reasons for him and other scientists to be optimistic. “For Covid-19, it’s clear most humans who get infected recover … that alone shows the human immune system can eliminate the virus,” he says. That makes it a much easier target than HIV, which he calls unprecedented in the history of vaccinology for its ability to evade the immune system. And the SARS-Cov2 virus doesn’t have the fast mutation rate that makes flu viruses a moving target.Art Krieg, a physician and founder of Checkmate Pharmaceuticals, says he’s very optimistic that because the human immune system can successfully battle the virus, so will one or more of the many experimental vaccines. All vaccines have to provide a danger signal to “prime” the immune system into acting against an invader. In 1995, Krieg reported the discovery one of these danger signals — called CpG DNA — which has been used in several vaccines, including one for hepatitis B, and is in some of the experimental candidates against the virus that causes Covid-19.Next, the vaccine has to mimic the invader in order to get the immune system to create specific antibodies that target the intended enemy. Vaccine designers using genetic material (DNA or RNA) have to stimulate the immune system enough to generate those antibodies, but not so much that the immune system destroys the vaccine before it can complete its mission.The biggest driver of recent headlines (and stock market drama) was a vaccine produced by the Massachusetts-based company Moderna, which is based on synthetic genetic material identical to parts of the code carried by the coronavirus. The genetic material is RNA — the single-stranded cousin of DNA. (Other RNA vaccines are being studied by BionTech, Translate Bio, and Curevac.) The RNA tricks human cells into making proteins identical to the “spike” proteins the virus uses to penetrate human cells. And that, in turn, stimulates the immune system to make antibodies that will be ready to block that protein if the real coronavirus invades.The excitement about Moderna’s vaccine followed the release of data from a trial that involved 45 volunteers, though the company only described results for eight of them. Of the eight, all produced antibodies with the desired “neutralizing” property needed to attack the virus in the future. What happened to the other 37 people? Since this vaccine requires two doses, they probably just didn’t have that data yet, says Krieg.A similar concept is behind DNA vaccines. The one developed by Harvard’s Barouch made the news for a successful experiment in monkeys. Other DNA vaccines are already in early human trials, including candidates developed by Oxford University, Johnson & Johnson and the Chinese company CanSino Biologics.These DNA vaccines use synthetic strings of code for making the spike protein carried by the virus. In some of these, the synthetic DNA is injected alone, while in others, it rides into human cells inside a deactivated cold virus (called an adenovirus). The human cells transcribe the DNA to RNA, and then into the decoy spike protein used to create immunity to the real thing. While the prototype developed by Barouch’s group at Harvard can be given in two shots, the Oxford DNA vaccine and several others that use cold viruses confer immunity with just one shot, says Krieg. DNA and RNA aren’t our only options. Yet another vaccine concept, made by Dynavax, uses the spike protein itself and stimulates the immune system using a synthetic DNA danger signal — the CpG DNA. These protein-based vaccines would have to be produced in bulk in fermentation vats, which Krieg says is something the biotech industry is equipped to do.Krieg says all the novel vaccines work through the same well-established scientific principles, and are very likely to be safe. Still, he says, it’s well known that vaccines don’t work as well in the elderly and immunocompromised. Imperfect vaccines could still eradicate the virus through herd immunity but only if the bulk of the population gets vaccinated. Once the technical hurdles are overcome, there will be social hurdles — already, there are movements among anti-vaxxers to resist — but it’s not too soon to plan to surmount them.Barouch says the ordinarily competitive nature of science has changed, as everyone understands how much is at stake in terms of lives and economic damage. In retrospect, critics might be able to criticize approaches that didn’t work, but right now, we need all the ideas we can get.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Faye Flam is a Bloomberg Opinion columnist. She has written for the Economist, the New York Times, the Washington Post, Psychology Today, Science and other publications. She has a degree in geophysics from the California Institute of Technology.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Motley Fool
If You're Retired, Consider Buying These 3 Stocks
Solid balance sheets, operations in critical industries, and rising dividends. What's not to love?
- Motley Fool
Is Arrowhead Pharmaceuticals a Buy?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
- Yahoo Finance
An 'unprecedented' effort to find a coronavirus vaccine has over 100 horses in the race
Vaccines are perceived as key to ending the restraints on work and life that have decimated the global economy, and returning to some sense of normalcy.
- Yahoo Finance
Some wellness products growing ‘over 1,000%’ during pandemic: Ro CEO
The coronavirus pandemic accelerated a wellness renaissance among consumers as shelter in place orders took effect, based on some of the sales trends seen by companies including Ro.
- Yahoo Finance
Telehealth is going to 'become the default' for patients: Ro CEO
Telehealth companies enabling individuals to see physicians without stepping foot into a physical doctor’s office are having their moment, as the coronavirus pandemic confines individuals and would-be patients across the country largely to their homes.
- Yahoo Finance
The race for a coronavirus treatment is fanning fears of 'vaccine nationalism'
Geopolitical rivalries, as well as practical considerations, are emerging as real hurdles in the race for a COVID treatment.
- Zacks
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
- Zacks
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain
Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.
- Motley Fool
FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck
Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option. The FDA on Wednesday approved Lynparza, a PARP inhibitor from AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) that previously had been approved to treat people with ovarian and breast cancers. The FDA completed its review of Lynparza for prostate cancer patients with tumors that test positive for homologous recombination repair (HRR) mutations a couple of months ahead of schedule.
- Motley Fool
Johnson & Johnson Plans to Stop Selling Talc-Based Baby Powder
On Tuesday, Johnson & Johnson (NYSE: JNJ) announced plans to discontinue sales of talc-based Johnson's Baby Powder as part of a larger reorganization of products sold by the healthcare conglomerate. The discontinuation of talc-based Johnson's Baby Powder in North America was due to declining sales of the talc-based products as customers worried about the potential to get cancer from the products. Johnson & Johnson is facing multiple lawsuits over the potential for talcum powder to cause cancer, potentially due to contamination with asbestos.
- Yahoo Finance
Sorrento Therapeutics CEO: We are not a 'pump and dump' scheme
Sorrento Therapeutics defends his company and some promising new technology to address the COVID-19 pandemic.
- Zacks
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, Fidelity National Information Services, Alibaba and Bristol-Myers Squibb
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, Fidelity National Information Services, Alibaba and Bristol-Myers Squibb
- Zacks
J&J to Stop Sale of Talc-Based Baby Powder in North America
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
- Zacks
Top Stock Reports for Facebook, JNJ, FIS & Others
Top Stock Reports for Facebook, JNJ, FIS & Others
- Motley Fool
Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
A double-sided antibody with blockbuster potential shrank tumors for relapsed multiple myeloma patients who have run out of treatment options.
- Bloomberg
Pandemic Seems to Last Forever. So Did Earnings Calls.
(Bloomberg Opinion) -- With the coronavirus pandemic turning the world’s economy upside down, analysts and investors have a lot of questions, and companies are doing their best to answer them. So if it feels like earnings calls were extra long these past few weeks, that’s because they were. Among the 29 members of the Dow Jones Industrial Average who normally have earnings calls and have held one since the beginning of March, 22 companies ran longer than usual by an average of about 10 minutes.Johnson & Johnson executives were the most verbose, with the company’s April 14 earnings call stretching about 1 hour and 43 minutes. That was nearly 26 minutes longer than the average of Johnson & Johnson’s previous four earnings calls. Even Walmart Inc., which doesn’t consistently hold public earnings calls, held an hour-long one on Tuesday to discuss first-quarter results. Analysts are generally grateful to have the extra information, but they, too, are noticing the longer calls. “Sorry, I was just fixing myself some dinner,” joked JPMorgan Chase & Co. analyst Steve Tusa in the middle of Emerson Electric Co.’s April 21 earnings call, which took place in the morning but stretched on a bit. “This is a pretty comprehensive conference call you’re having here.” Emerson, which isn’t a member of the Dow, included presentations by its major business heads as well as the CEO, CFO and company president. All told, the call lasted more than 2 hours, about 45 minutes longer than the recent average. It’s probably wise to stockpile snacks ahead of the next round of calls in July. This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Brooke Sutherland is a Bloomberg Opinion columnist covering deals and industrial companies. She previously wrote an M&A column for Bloomberg News.Elaine He is Bloomberg Opinion's data visualization columnist in Europe, focusing on business and markets coverage. Before joining Bloomberg, she was a graphics editor at the Wall Street Journal and the New York Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Yahoo Finance
Market pros have high hopes for a COVID-19 vaccine: Morning Brief
Top news and what to watch in the markets on Tuesday, May 19, 2020.
- Financial Times
Johnson & Johnson stops selling talc-based baby powder
Johnson & Johnson will stop selling its baby talcum powder in the US and Canada, where sales have dropped amid a wave of litigation claiming that the personal care product can cause cancer. The world’s largest healthcare company said sales of the powder had dropped 60 per cent in the past three years, as it had been hit with thousands of lawsuits and billions of dollars in damages at trial over the claims. Kathleen Widmer, chairman of North America for Johnson & Johnson’s consumer health division, said advertising from lawyers seeking new clients to sue the company had confused customers and caused sales to fall.
- Motley Fool
3 Dividend Stocks Perfect for Retirees
The mix of retirement income sources has changed dramatically over the years. Not too terribly long ago, employer pensions supplied much of an individual's needed income after their working years had ended.
- Motley Fool
Is Buying a Basket Loaded With Every Coronavirus Vaccine Stock a Smart Strategy?
The entire world anxiously awaits good news in the race to develop a vaccine for novel coronavirus disease COVID-19. And there are plenty of drugmakers hoping to be the bearers of some good news, including both big pharmaceutical companies and small biotechs.
